1 week Ago By Defense World Staff
Prudential Financial Inc. decreased its holdings in shares of Lyell Immunopharma, Inc. ( NASDAQ:LYEL – Free Report ) by 66.
8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,057 shares of the company’s stock after selling 96,900 shares during the quarter. Prudential Financial Inc.
’s holdings in Lyell Immunopharma were worth $31,000 as of its most recent SEC filing. Several other institutional investors have also bought and sold shares of LYEL. Barclays PLC increased its holdings in shares of Lyell Immunopharma by 312.
7% in the 3rd quarter. Barclays PLC now owns 240,615 shares of the company’s stock worth $332,000 after buying an additional 182,315 shares during the last quarter. SG Americas Securities LLC increased its stake in Lyell Immunopharma by 102.
8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock worth $75,000 after acquiring an additional 59,182 shares during the last quarter. Jane Street Group LLC raised its position in Lyell Immunopharma by 63.
7% during the third quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock valued at $397,000 after purchasing an additional 111,917 shares during the period. State Street Corp lifted its stake in shares of Lyell Immunopharma by 1.
9% in the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after purchasing an additional 71,233 shares during the last quarter. Finally, Charles Schwab Investment Management Inc.
boosted its holdings in shares of Lyell Immunopharma by 43.4% in the 4th quarter. Charles Schwab Investment Management Inc.
now owns 1,645,787 shares of the company’s stock worth $1,053,000 after purchasing an additional 498,417 shares during the period. Institutional investors own 66.05% of the company’s stock.
Wall Street Analyst Weigh In Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a report on Thursday, March 13th. Insider Buying and Selling at Lyell Immunopharma In related news, CFO Charles W.
Newton purchased 200,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $0.56 per share, with a total value of $112,000.
00. Following the completion of the purchase, the chief financial officer now owns 200,000 shares of the company’s stock, valued at approximately $112,000. The trade was a ∞ increase in their position.
The acquisition was disclosed in a filing with the SEC, which is available at the SEC website . Also, CEO Lynn Seely purchased 175,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average price of $0.
61 per share, with a total value of $106,750.00. Following the acquisition, the chief executive officer now directly owns 712,500 shares of the company’s stock, valued at $434,625.
This trade represents a 32.56 % increase in their position. The disclosure for this purchase can be found here .
Insiders have acquired 768,640 shares of company stock valued at $449,508 in the last quarter. 25.10% of the stock is owned by insiders.
Lyell Immunopharma Trading Up 5.7 % Shares of NASDAQ:LYEL opened at $0.44 on Friday.
Lyell Immunopharma, Inc. has a 12 month low of $0.39 and a 12 month high of $3.
15. The company has a market capitalization of $129.46 million, a price-to-earnings ratio of -0.
56 and a beta of -0.26. The firm’s 50-day moving average is $0.
58 and its 200 day moving average is $0.79. Lyell Immunopharma ( NASDAQ:LYEL – Get Free Report ) last released its earnings results on Wednesday, March 12th.
The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.
52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.
64%. The business had revenue of $0.01 million for the quarter.
As a group, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.
Lyell Immunopharma Profile ( Free Report ) Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. Read More Five stocks we like better than Lyell Immunopharma Insider Buying Explained: What Investors Need to Know JPMorgan is a Buy, if You Can Handle The Volatility What is the Hang Seng index? United States Steel’s Crash: An Unmissable Buying Opportunity The Role Economic Reports Play in a Successful Investment Strategy Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding LYEL? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Lyell Immunopharma, Inc. ( NASDAQ:LYEL – Free Report ). Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.
com's FREE daily email newsletter ..
